PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update

• Recruitment Progressing as Planned with Nearly 200 Patients Enrolled into Phase 3 SHIELD I Trial of D-PLEX 100 in Abdominal Surgery • Recruitment Rate in SHIELD I trial Doubled in the Last Three Weeks • Manufacturing Facility Now Fully Scaled Up and Capable of Supporting at Least First 30 Months